Synonym
Fenoterol, Berotec, p Hydroxyphenylorciprenaline, Partusisten, Phenoterol; Fenoterolum; NSC 757811; NSC757811; NSC-757811
IUPAC/Chemical Name
5-[1-hydroxy-2-[1-(4-hydroxyphenyl)propan-2-ylamino]ethyl]benzene-1,3-diol
InChi Key
LSLYOANBFKQKPT-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H21NO4/c1-11(6-12-2-4-14(19)5-3-12)18-10-17(22)13-7-15(20)9-16(21)8-13/h2-5,7-9,11,17-22H,6,10H2,1H3
SMILES Code
OC1=CC(C(O)CNC(C)CC2=CC=C(O)C=C2)=CC(O)=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
303.35
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Jozwiak K, Plazinska A, Toll L, Jimenez L, Woo AY, Xiao RP, Wainer IW. Effect of fenoterol stereochemistry on the β2 adrenergic receptor system: ligand-directed chiral recognition. Chirality. 2011;23 Suppl 1:E1-6. doi: 10.1002/chir.20963. Epub 2011 May 26. Review. PubMed PMID: 21618615; PubMed Central PMCID: PMC3164500.
2: Kässner F, Hodder R, Bateman ED. A review of ipratropium bromide/fenoterol hydrobromide (Berodual) delivered via Respimat Soft Mist Inhaler in patients with asthma and chronic obstructive pulmonary disease. Drugs. 2004;64(15):1671-82. Review. PubMed PMID: 15257628.
3: Beasley R, Pearce N, Crane J, Burgess C. Withdrawal of fenoterol and the end of the New Zealand asthma mortality epidemic. Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):325-7. Review. PubMed PMID: 7613161.
4: Hochhaus G, Möllmann H. Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol Ther Toxicol. 1992 Sep;30(9):342-62. Review. PubMed PMID: 1358833.
5: Boe J, Kongerud J, Bodd E. [Is fenoterol therapy related to increased asthma mortality?]. Tidsskr Nor Laegeforen. 1992 Feb 20;112(5):661-3. Review. Norwegian. PubMed PMID: 1557737.
6: Fenoterol and asthma deaths. Drug Ther Bull. 1990 Dec 10;28(25):65-6. Review. PubMed PMID: 2131236.
7: Elwood JM. Fenoterol: the evidence leading to restriction of it use. N Z Med J. 1990 Aug 22;103(896):395-7. Review. PubMed PMID: 2200989.
8: Svedmyr N. Fenoterol: a beta2-adrenergic agonist for use in asthma. Pharmacology, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy. 1985 May-Jun;5(3):109-26. Review. PubMed PMID: 2991865.
9: Meinen K. [Does tocolysis with fenoterol cause myocardial necrosis?]. Z Geburtshilfe Perinatol. 1983 Sep-Oct;187(5):209-17. Review. German. PubMed PMID: 6359742.
10: Heel RC, Brogden RN, Speight TM, Avery GS. Fenoterol: a review of its pharmacological properties and therapeutic efficacy in asthma. Drugs. 1978 Jan;15(1):3-32. Review. PubMed PMID: 342228.
